Newsroom | 1748 results

LOS ANGELES--(BUSINESS WIRE)--Gilead's Earnings per Share Expected to Be Up 52% as Florida’s and other States’ AIDS Drug Programs Falters, says AHF...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed. The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of Aug...

LOS ANGELES--(BUSINESS WIRE)--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities...

BOSTON--(BUSINESS WIRE)--Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Jaison Ellis has joined the firm as a Managing Director, based in Charlotte, NC. The firm continues to expand its life sciences and healthcare practices through its unique, market-aligned, strategy-driven platform, delivering mergers and acquisitions, partnerships, and strategic advisory services. “I’m delighted to join such a distinguished...

MIAMI--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Will Equity Prevail? The PABS Annex Negotiations at Their Final Hour,” on Thursday, April 23, 2026 at 10:00 AM EDT, virtually via Zoom. Register here. As WHO Pandemic Agreement negotiations enter a decisive phase ahead of the next Intergovernmental Working Group (IGWG) session, Member States are working to finalize the Pathogen Access and Bene...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Launches Statewide Campaign Urging Full Restoration of Florida's AIDS Drug Assistance Program...

SAN FRANCISCO--(BUSINESS WIRE)--WellTheory, a whole-person care platform for autoimmune disease, announced it is expanding its partnership with the Self-Insured Schools of California (SISC), the largest public school pool in the US. Following a year-long pilot and independent actuarial validation, SISC rolled out WellTheory’s proprietary program to its entire PPO membership, making services available to hundreds of thousands of eligible public school employees and their families across Californ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together th...

SAN FRANCISCO--(BUSINESS WIRE)--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing...